- Authors:
-
Leonetti, Alessandro; Perrone, Fabiana; Puntoni, Matteo; Maglietta, Giuseppe; Bordi, Paola; Bria, Emilio; Vita, Emanuele; Gelsomino, Francesco; De Giglio, Andrea; Gelibter, Alain; Siringo, Marco; Mazzoni, Francesca; Caliman, Enrico; Genova, Carlo; Bertolini, Federica; Guaitoli, Giorgia; Passiglia, Francesco; Delcuratolo, Marco Donatello; Montrone, Michele; Cerea, Giulio; Pasello, Giulia; Roca, Elisa; Belluomini, Lorenzo; Cecere, Fabiana Letizia; Guida, Annalisa; Manzo, Anna; Adamo, Vincenzo; Rastelli, Francesca; Bulotta, Alessandra; Citarella, Fabrizio; Toschi, Luca; Zoratto, Federica; Cortinovis, Diego Luigi; Berardi, Rossana; Follador, Alessandro; Carta, Annamaria; Camerini, Andrea; Salerno, Flavio; Silva, Rosa Rita; Baldini, Editta; Cortellini, Alessio; Brighenti, Matteo; Santoni, Matteo; Malorgio, Francesco; Caminiti, Caterina; Tiseo, Marcello
- Title:
-
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
- Year:
-
2024
- Type of item:
-
Articolo in Rivista
- Tipologia ANVUR:
- Articolo su rivista
- Language:
-
Inglese
- Referee:
-
No
- Name of journal:
- European Journal of Cancer
- ISSN of journal:
- 0959-8049
- N° Volume:
-
202
- Page numbers:
-
114006-114006
- Keyword:
-
Non-Small-Cell Lung Carcinoma; Pembrolizumab: Platinum chemotherapy; Pemetrexed; Real-world
- Short description of contents:
- Purpose: The aim of this multi -center, retrospective/prospective cohort observational study was to evaluate outcomes in routine clinical practice of first -line chemo-immunotherapy with cis/carboplatin, pemetrexed and pembrolizumab in patients with advanced non-squamous non -small cell lung cancer (NSCLC) in 33 Italian centers. Methods: The outcome measure was to evaluate overall survival (OS) in a real -world patient population. Secondary endpoints were: progression -free survival (PFS), objective response rate (ORR), duration of response (DoR) and incidence of treatment -related adverse events (AEs). Results: 1068 patients were enrolled at the time of data cut-off (January 31st, 2023), and 812 (76.0%) belonged to the retrospective cohort. Median age was 66 years (27-85), ECOG PS was >= 2 in 91 (8.6%) patients; 254 (23.8%) patients had brain metastases at baseline; 38 (3.6%) patients had tumor with PD -L1 expression >= 50%. After a median follow-up of 17.0 months (95% CI, 16.1-17.9), median OS was 16.1 months (95% CI, 14.4-18.8) and PFS was 9.9 months (95% CI, 8.8-11.2). Median DoR (n = 493) was 14.7 months (95% CI, 13.6-17.1). ORR was 43.4% (95% CI, 40.4-46.4). Any -grade AEs occurred in 636 (59.6%) patients and grade >= 3 in 253 (23.7%) patients. Most common grade >= 3 AEs were neutropenia (6.3%) and anemia (6.3%). Conclusions: First -line chemo-immunotherapy was effective and tolerable in this large, real -world Italian study of patients with advanced non-squamous NSCLC. Our results were in line with the KEYNOTE -189 registration study, also considering the low number of PD -L1 >= 50% patients included in our study.
- Product ID:
-
141562
- Handle IRIS:
-
11562/1140868
- Last Modified:
-
October 30, 2024
- Bibliographic citation:
-
Leonetti, Alessandro; Perrone, Fabiana; Puntoni, Matteo; Maglietta, Giuseppe; Bordi, Paola; Bria, Emilio; Vita, Emanuele; Gelsomino, Francesco; De Giglio, Andrea; Gelibter, Alain; Siringo, Marco; Mazzoni, Francesca; Caliman, Enrico; Genova, Carlo; Bertolini, Federica; Guaitoli, Giorgia; Passiglia, Francesco; Delcuratolo, Marco Donatello; Montrone, Michele; Cerea, Giulio; Pasello, Giulia; Roca, Elisa; Belluomini, Lorenzo; Cecere, Fabiana Letizia; Guida, Annalisa; Manzo, Anna; Adamo, Vincenzo; Rastelli, Francesca; Bulotta, Alessandra; Citarella, Fabrizio; Toschi, Luca; Zoratto, Federica; Cortinovis, Diego Luigi; Berardi, Rossana; Follador, Alessandro; Carta, Annamaria; Camerini, Andrea; Salerno, Flavio; Silva, Rosa Rita; Baldini, Editta; Cortellini, Alessio; Brighenti, Matteo; Santoni, Matteo; Malorgio, Francesco; Caminiti, Caterina; Tiseo, Marcello,
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
«European Journal of Cancer»
, vol.
202
,
2024
,
pp. 114006-114006
Consulta la scheda completa presente nel
repository istituzionale della Ricerca di Ateneo